LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
A live webcast of the fireside chat will be made available on the Investors section of the Company's website at www.logicbio.com/investors. The webcast replay will be available for approximately 30 days.
About LogicBio Therapeutics
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company's gene editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The Company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The Company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.
Investor Contacts:
(619) 916-7620
laurence@gilmartinir.com
(858) 525-2047
stephen@gilmartinir.com
Media Contacts:
Berry & Company Public Relations
W: 212-253-8881
C: 614-580-2048
adaley@berrypr.com
Berry & Company Public Relations
W: 212-253-8881
C: 203-218-9180
jurban@berrypr.com
View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-participate-in-the-2021-cantor-virtual-global-healthcare-conference-301384769.html
SOURCE